glp 1 gip glucagon triple agonist retatrutide glp-1 phase 3 2025 Dual and Triple Gut Peptide Agonists Retatrutide: How the Triple Agonist

DPP-4 Inhibitors: review of vildagliptin phase 3 data

[10] [11] Other potential adverse effects observed with GLP-1 receptor agonists include: Injection site reactions: Redness, swelling, or discomfort at the injection site Fatigue and dizziness: Particularly during the initial treatment period Increased heart rate: A modest elevation in resting heart rate has been noted with GLP-1 agonists [12] [13] Hypoglycaemia: Risk is low when used alone but increases if combined with insulin or sulphonylureas Serious safety considerations require careful monitoring

during the third week, administer two tablets in the morning and one tablet in the evening

Waldrop G, Zhong J, Peters M, Rajagopalan S

DOI: Published online: April 25, 2016 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Curr Opin Pharmacol